Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tonix Pharma ( (TNXP) ) has issued an announcement.
On July 21, 2025, Tonix Pharmaceuticals Holding Corp. announced the launch of its Move Fibro Forward campaign, aimed at raising awareness and providing support to individuals living with fibromyalgia. This initiative reflects the company’s commitment to addressing central nervous system disorders and could enhance its market positioning by highlighting its dedication to patient support and advocacy.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall stock score reflects strong technical momentum and positive corporate developments, counterbalanced by profitability challenges and a high-risk valuation profile. The company’s strategic moves in clinical advancements and market expansion are promising, but financial sustainability remains a concern.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative pharmaceutical products. The company is particularly involved in creating treatments for central nervous system disorders, immunology, and infectious diseases.
Average Trading Volume: 975,248
Technical Sentiment Signal: Sell
Current Market Cap: $345.1M
For a thorough assessment of TNXP stock, go to TipRanks’ Stock Analysis page.